Disciplina Capital Management LLC Raises Stake in Novo Nordisk A/S $NVO

Disciplina Capital Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 162.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 480 shares of the company’s stock after buying an additional 297 shares during the period. Disciplina Capital Management LLC’s holdings in Novo Nordisk A/S were worth $33,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $29,000. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $33,000. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $27,000. Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after purchasing an additional 255 shares during the period. Finally, Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $30,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 2.9%

Shares of NVO stock opened at $52.43 on Monday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The firm has a market capitalization of $234.10 billion, a PE ratio of 14.40, a P/E/G ratio of 1.80 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock’s 50-day simple moving average is $64.96 and its 200-day simple moving average is $70.24.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 45.05%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Hsbc Global Res downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $83.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.